soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Reduces CV Events in T2DM – (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉 Oral Semaglutide and Cardiovascular Outcomes

Hao et al., 1994)

Growth hormone receptors have been identified in hair follicle cells, and GH signaling appears to influence the duration and vigor of the anagen phase

Additionally, the growing cases of cardiovascular diseases and obesity are also contributing to their increased demand for GLP-1 drugs

March 13, 2026: FDA Sends Warning Letter to Novo Nordisk The FDA has sent a warning letter to the maker of Ozempic and Wegovy over a potential failure to report side effects connected to these drugs

They affect approximately 1 in 10 people in the UK at some point in their lives, with men being more commonly affected than women